基于血液的迁移特征生物标志物面板可区分早期新发糖尿病相关胰腺导管腺癌与 2 型糖尿病。

Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes.

机构信息

Department of Translational Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

出版信息

Clin Chim Acta. 2023 Nov 1;551:117567. doi: 10.1016/j.cca.2023.117567. Epub 2023 Sep 27.

DOI:10.1016/j.cca.2023.117567

PMID:37774897

Abstract

BACKGROUND AND AIMS

While type 2 diabetes is a well-known risk factor for pancreatic ductal adenocarcinoma (PDAC), PDAC-induced new-onset diabetes (PDAC-NOD) is a manifestation of underlying PDAC. In this study, we sought to identify potential blood-based biomarkers for distinguishing PDAC-NOD from type 2 diabetes (T2DM) without PDAC.

MATERIALS AND METHODS

By ELISA analysis, a migration signature biomarker panel comprising tissue factor pathway inhibitor (TFPI), tenascin C (TNC-FNIII-C) and CA 19-9 was analyzed in plasma samples from 50 PDAC-NOD and 50 T2DM controls.

RESULTS

Both TFPI (area under the curve (AUC) 0.71) and TNC-FNIII-C (AUC 0.69) outperformed CA 19-9 (AUC 0.60) in distinguishing all stages of PDAC-NOD from T2DM controls. The combined panel showed an AUC of 0.82 (95% CI = 0.73-0.90) (p = 0.002). In the PDAC-NOD early stage II samples, the three biomarkers had an AUC of 0.84 (95% CI = 0.73-0.93) vs CA 19-9, AUC = 0.60, (95% CI = 0.45-0.73), which also improved significance (p = 0.0123).

CONCLUSION

The migration signature panel adds significantly to CA 19-9 to discriminate PDAC-NOD from T2DM controls and warrants further validation for high-risk group stratification.

摘要

背景与目的

虽然 2 型糖尿病是胰腺导管腺癌（PDAC）的已知危险因素，但 PDAC 引起的新发糖尿病（PDAC-NOD）是 PDAC 潜在的表现。在这项研究中，我们试图确定潜在的基于血液的生物标志物，以区分 PDAC-NOD 与无 PDAC 的 2 型糖尿病（T2DM）。

材料和方法

通过 ELISA 分析，对来自 50 名 PDAC-NOD 和 50 名 T2DM 对照者的血浆样本中组织因子途径抑制剂（TFPI）、腱生蛋白 C（TNC-FNIII-C）和 CA 19-9 的迁移特征生物标志物谱进行分析。

结果

TFPI（AUC 0.71）和 TNC-FNIII-C（AUC 0.69）在区分所有阶段的 PDAC-NOD 与 T2DM 对照者方面均优于 CA 19-9（AUC 0.60）。联合谱显示 AUC 为 0.82（95%CI=0.73-0.90）（p=0.002）。在 PDAC-NOD 早期阶段 II 样本中，这三个生物标志物的 AUC 为 0.84（95%CI=0.73-0.93），而 CA 19-9 的 AUC 为 0.60（95%CI=0.45-0.73），这也提高了显著性（p=0.0123）。